{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:55:23Z","timestamp":1788872123749,"version":"build-2803163510"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,1,30]],"date-time":"2015-01-30T00:00:00Z","timestamp":1422576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["iCLO155"],"award-info":[{"award-number":["iCLO155"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:p>\n                    Prior study of the combination of clofarabine and high dose cytarabine with granulocyte colony\u2010stimulating factor (G\u2010CSF) priming (GCLAC) in relapsed or refractory acute myeloid leukemia resulted in a 46% rate of complete remission despite unfavorable risk cytogenetics. A multivariate analysis demonstrated that the remission rate and survival with GCLAC were superior to FLAG (fludarabine, cytarabine, G\u2010CSF) in the relapsed setting. We therefore initiated a study of the GCLAC regimen in the upfront setting in a multicenter trial. The objectives were to evaluate the rates of complete remission (CR), overall and relapse\u2010free survival (OS and RFS), and toxicity of GCLAC. Clofarabine was administered at 30 mg\u00a0m\n                    <jats:sup>\u22122\u00a0<\/jats:sup>\n                    day\n                    <jats:sup>\u22121<\/jats:sup>\n                    \u00d7 5 and cytarabine at 2 g\u00a0m\n                    <jats:sup>\u22122\u00a0<\/jats:sup>\n                    day\n                    <jats:sup>\u22121<\/jats:sup>\n                    \u00d7 5 after G\u2010CSF priming in 50 newly\u2010diagnosed patients ages 18\u201364 with AML or advanced myelodysplastic syndrome (MDS) or advanced myeloproliferative neoplasm (MPN). Responses were assessed in the different cytogenetic risk groups and in patients with antecedent hematologic disorder. The overall CR rate was 76% (95% confidence interval [CI] 64\u201388%) and the CR\u2009+\u2009CRp (CR with incomplete platelet count recovery) was 82% (95% CI 71\u201393%). The CR rate was 100% for patients with favorable, 84% for those with intermediate, and 62% for those with unfavorable risk cytogenetics. For patients with an antecedent hematologic disorder (AHD), the CR rate was 65%, compared to 85% for those without an AHD. The 60 day mortality was 2%. Thus, front line GCLAC is a well\u2010tolerated, effective induction regimen for AML and advanced myelodysplastic or myeloproliferative disorders. Am. J. Hematol. 90:295\u2013300, 2015. \u00a9 2014 Wiley Periodicals, Inc.\n                  <\/jats:p>","DOI":"10.1002\/ajh.23927","type":"journal-article","created":{"date-parts":[[2014,12,24]],"date-time":"2014-12-24T05:59:11Z","timestamp":1419400751000},"page":"295-300","source":"Crossref","is-referenced-by-count":14,"title":["G\u2010CSF\n                    <scp>P<\/scp>\n                    riming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm"],"prefix":"10.1002","volume":"90","author":[{"given":"Pamela S.","family":"Becker","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine University of Washington Seattle Washington"},{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno C.","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Medicine Stanford School of Medicine Palo Alto California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony S.","family":"Stein","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation City of Hope Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Othus","sequence":"additional","affiliation":[{"name":"Public Health Sciences Division Fred Hutchinson Cancer Research Center Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R.","family":"Appelbaum","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle Washington"},{"name":"Division of Medical Oncology, Department of Medicine University of Washington Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation City of Hope Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart L.","family":"Scott","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle Washington"},{"name":"Division of Medical Oncology, Department of Medicine University of Washington Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Hendrie","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine University of Washington Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelda M.","family":"Gardner","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine University of Washington Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Pagel","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle Washington"},{"name":"Division of Medical Oncology, Department of Medicine University of Washington Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine University of Washington Seattle Washington"},{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Parks","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine University of Washington Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent L.","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine University of Washington Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis L.","family":"Abkowitz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine University of Washington Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elihu H.","family":"Estey","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine University of Washington Seattle Washington"},{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,1,30]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3294"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-124602"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.9743"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08831.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.063438"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-357-2_8"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"4075\u20134083","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group\/Eastern Cooperative Oncology Group Study","volume":"96","author":"Slovak ML","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27429"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.242"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-496596"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2002.01651.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"crossref","unstructured":"BorthakurG CortesJE EsteyEE et al.Gemtuzumab ozogamicin with fludarabine cytarabine and granulocyte colony stimulating factor (FLAG\u2010GO) as front\u2010line regimen in patients with core binding factor acute myelogenous leukemia.Am J Hematol2014;89:964\u2212968.","DOI":"10.1002\/ajh.23795"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.30"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23927"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.01.009"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-506725"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.9628"},{"key":"e_1_2_6_21_1","doi-asserted-by":"crossref","unstructured":"FernandezHF SunZ YaoX et al.Anthracycline dose intensification in acute myeloid leukemia.N Engl J Med2009;361:1249\u22121259.","DOI":"10.1056\/NEJMoa0904544"},{"key":"e_1_2_6_22_1","unstructured":"L\u00f6wenbergB OssenkoppeleGJ vanPuttenW et al.High\u2010dose daunorubicin in older patients with acute myeloid leukemia.N Engl J Med2009;361:1235\u22121248."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-466706"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23544"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00988.x"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23927","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23927","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:32:43Z","timestamp":1695551563000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,30]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1002\/ajh.23927"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23927","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,30]]}}}